CLGN
CollPlant Biotechnologies Ltd.
CLGN lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
CLGN Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Strong |
CLGN's balance sheet is currently strong, but its revenue, profitability and cash flow are weak.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
CLGN PE Valuation
CLGN has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
CLGN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect CLGN's losses to shrink, with revenue declining.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
CLGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$9.39 | +$1.91 |
| Q1 2026 | -$10.30 | +$1.90 |
| Q4 2025 | -$9.30 | +$5.30 |
| Q3 2025 | -$10.20 | +$5.10 |
| Q2 2025 | -$11.30 | +$4.00 |
| Q1 2025 | -$12.20 | -$5.50 |
| Q4 2024 | -$14.60 | -$8.10 |
| Q3 2024 | -$15.30 | -$9.20 |
CLGN has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
CLGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $108K | -40% |
| Q1 2026 | $73K | -96% |
| Q4 2025 | $60K | -63% |
| Q3 2025 | $77K | +1825% |
| Q2 2025 | $179K | -28% |
| Q1 2025 | $2.1M | +1997% |
| Q4 2024 | $164K | -45% |
| Q3 2024 | $4K | -91% |
CLGN's revenue has slid since its 2021 peak: $108,000 last quarter, down 40% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -2438% | -663 points |
| Q1 2026 | -4267% | -4187 points |
| Q4 2025 | -5250% | -2827 points |
| Q3 2025 | -4555% | +108995 points |
| Q2 2025 | -1775% | -5.9 points |
| Q1 2025 | -80% | +4337 points |
| Q4 2024 | -2423% | -728 points |
| Q3 2024 | -113550% | -102848 points |
CLGN's operating margin was −2438% last quarter, down 663 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over CLGN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over CLGN on profitability, with a higher operating margin.
CLGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2.5M | -$99K |
| Q1 2026 | -$3.1M | -$1.9M |
| Q4 2025 | -$3.2M | +$296.9K |
| Q3 2025 | -$2.9M | +$710K |
| Q2 2025 | -$2.4M | +$1.7M |
| Q1 2025 | -$1.2M | +$2.2M |
| Q4 2024 | -$3.5M | -$949K |
| Q3 2024 | -$3.6M | -155% |
CLGN has burned cash in almost every quarter: −$12M over the past year, against −$11M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over CLGN on cash generation, producing positive trailing cash flow while its opponent burns cash.
CLGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.9% | +67.9K shares |
| 1 year | +22% | +259K shares |
| 3 years | +22% | +265K shares |
| 5 years | +41% | +423K shares |
| Available history | +209% | +976K shares |
CLGN has 1M diluted shares, up 22% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
CLGN hasn't bought back shares in the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over CLGN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
CLGN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2021 | -9.1x | Net Cash |
| Q3 2021 | -11.9x | Net Cash |
| Q2 2021 | -2.5x | Net Cash |
| Q1 2021 | -2.5x | Net Cash |
CLGN has more cash than debt.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
CLGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 49.8 | Neutral |
| Stochastic | 23.1 | Neutral |
CLGN's weekly RSI is 50 (neutral) and its Stochastic is 23 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
CLGN PE vs Healthcare Sector
CLGN has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
CLGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.91 | 19% above |
| 20 week MA | $3.63 | 28% above |
| 50 week MA | $6.53 | 29% below |
| 100 week MA | $16.3 | 72% below |
| 200 week MA | $39.0 | 88% below |
CLGN has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
CLGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $58.0 | $100.5 | +73% |
| 2021 | $100.5 | $132.2 | +32% |
| 2022 | $132.2 | $83.4 | -37% |
| 2023 | $83.4 | $63.9 | -23% |
| 2024 | $63.9 | $35.7 | -44% |
| 2025 | $35.7 | $15.3 | -57% |
| 2026 YTD | $15.3 | $4.64 | -70% |
CLGN has finished four years in a row lower, and it's down 70% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over CLGN on returns for 2026, with the stronger performance.